Penny Stocks To Watch For The New Year
Heading into the New Year, penny stocks are red hot, and for good reason. While the broader markets themselves have been relatively flat this week, stocks under $5 a/k/a âpenny stocksâ have offered significant levels of volatility. This is what day traders look for, of course. Now if youâre looking for ways to invest (vs trade), volatility might not be something you strive to find. Needless to say, these cheap stocks are more known for their short-term breakouts than anything else.
This isnât to say that all penny stocks should only be traded. This is also saying that not all penny stocks are bad to invest in. Everyone has their own strategy, obviously. But I feel like this fact needs to be hit home a bit harder in light of recent trends. This âtrendâ Iâm referring to is the lack of followthrough that many of these penny stock breakouts have seen. Take ATIF Holdings (ATIF Stock Report) this week, for instanc
Top Penny Stocks To Watch Before 2021 If You Like Biotech Stocks
Biotech Penny Stocks To Watch With Recent Updates
It’s funny to think that 2020 is almost over yet penny stocks remain a major focus for traders right now. One of the main reasons for this has been the unrelenting focus on volatility. Believe it or not, I think 2020 was pivotal for day trading, in general. While the pandemic lockdowns, social distancing, and negative economic impact were obviously hard on everyone this year, it created a new opportunity for those looking to make extra money. This, in turn, saw millions – yes millions – flock to the market.
Leading BioSciences and Seneca Biopharma Announce Merger
GERMANTOWN, Md. and CARLSBAD, Calif., Dec. 17, 2020 /PRNewswire/ Seneca Biopharma, Inc. (Nasdaq: SNCA) ( Seneca ), and Leading BioSciences, Inc. ( LBS ), a privately held company focused on developing novel therapeutics to improve human health through therapeutic protection of the gastrointestinal ( GI ) mucosal barrier, announced today that they have entered into a definitive agreement under which a wholly owned subsidiary of Seneca will merge with LBS in an all-stock transaction. The combined company will focus on advancing LBS s lead pipeline asset, LB1148, in clinical studies to evaluate its potential to improve restoration of normal GI function following major surgery and reduce certain postoperative complications such as abdominal adhesions. Upon completion of the merger, the company is expected to operate under the name Palisade Bio, Inc. and trade on the Nasdaq Capital Market under the ticker symbol PALI.